|
In an effort to advance high-quality healthcare standards and strengthening the regulatory framework, the Indian Pharmacopoeia Commission (IPC) signed a Memorandum of Understanding (MoU) with the Uttar Pradesh Promote Pharma Council (UPPPC). The MoU was signed during the YEIDA MedTech Investors Meet & Site Visit 2026, held on 14th July, 2026 at the India Expo Mart, Greater Noida.
The strategic collaboration aims to strengthen the pharmaceutical and medical device ecosystem by promoting quality standards, regulatory excellence, innovation, and capacity building across the sector.
Through the partnership, IPC and UPPPC are expected to work together to strengthen quality standards and regulatory compliance in the pharmaceutical and medical device industries; promote awareness of the Indian Pharmacopoeia, pharmacovigilance, and materiovigilance; organize joint training programmes, workshops, and stakeholder awareness initiatives, foster research, innovation, and industry–academia collaborations; support MSMEs by providing digital tools for adverse event reporting; and enhance patient safety through quality assurance and post-market surveillance initiatives.
The MoU reflects IPC's continued commitment to advancing high-quality healthcare standards, supporting innovation, and strengthening India's regulatory framework while contributing to the growth of Uttar Pradesh as a leading hub for pharmaceuticals, medical devices, and healthcare technologies.
The partnership strives to build a stronger ecosystem that promotes quality, safety, innovation, and global competitiveness, said the Union ministry of health and family welfare.
|